source
- UniQure tumbles with latest data for Huntington’s gene therapyAnalysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."BioPharma Dive · 1mo ago↗ source
- UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 yearsThe results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2…BioSpace · 1mo ago↗ source
- Merck pulls Recarbrio antibiotic from U.S. market, raising concerns over superbug resistanceMerck announced it has stopped supplying Recarbrio in the United States earlier this month. Recarbrio, a three‑drug combination injection approved seven years ago, is used for severe infections su…